LABORATORY MONITORING OF METABOLIC SAFETY DURING CARIPRAZINE TREATMENT IN SCHIZOPHRENIA AND BIPOLAR DISORDER: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.5550Keywords:
Cariprazine; Metabolic Safety; Laboratory Monitoring; Schizophrenia; Bipolar DisorderAbstract
Introduction: Metabolic adverse effects are a major concern during long-term antipsychotic treatment because they contribute to cardiovascular complications, endocrine disturbances, and reduced treatment adherence. Cariprazine has been considered an antipsychotic with a relatively favorable metabolic profile, but the available evidence is dispersed across studies of schizophrenia and bipolar disorder. This systematic review evaluated the laboratory-monitored metabolic safety of cariprazine in these populations.
Methods: This systematic review was conducted in accordance with PRISMA 2020 guidelines. PubMed/Medline and EMBASE were searched for studies published between 2014 and 2026 using the phrase: (cariprazine OR VRAYLAR) AND (schizophrenia OR schizophreni OR "bipolar disorder" OR bipolar) AND (safety OR tolerability OR "adverse effects" OR metabol OR prolactin OR weight OR glucose OR lipid*). After screening and full-text assessment, 11 studies met the eligibility criteria and were included in the qualitative synthesis.
Results: Across the included studies, cariprazine was associated mainly with modest body weight increase and limited changes in glucose- and lipid-related laboratory markers. Short-term and long-term studies in schizophrenia did not indicate a consistent pattern of clinically significant metabolic deterioration. Similar findings were reported in bipolar mania and bipolar depression. Prolactin-related data suggested minimal endocrine burden.
Conclusions: Cariprazine appears to have a comparatively favorable laboratory-monitored metabolic safety profile in schizophrenia and bipolar disorder. However, regular monitoring of body weight and biochemical parameters remains necessary, and further long-term studies with standardized metabolic endpoints are needed.
References
Pillinger, T., McCutcheon, R. A., Vano, L., Mizuno, Y., Arumuham, A., Hindley, G., Beck, K., Natesan, S., Efthimiou, O., Cipriani, A., & Howes, O. D. (2020). Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis. The Lancet Psychiatry, 7(1), 64–77. https://doi.org/10.1016/S2215-0366(19)30416-X
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., Alda, M., MacQueen, G., Milev, R. V., Ravindran, A., O’Donovan, C., McIntosh, D., Lam, R. W., Vazquez, G., Kapczinski, F., . . . Berk, M. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 20(2), 97–170. https://doi.org/10.1111/bdi.12609
Selvan, P., Devkare, P., Shetty, A., Dharmadhikari, S., Khandhedia, C., Mane, A., Mehta, S., & Andrade, C. (2024). A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophrenia. Frontiers in Psychiatry, 15, Article 1385925. https://doi.org/10.3389/fpsyt.2024.1385925
Misiak, B., Bieńkowski, P., & Samochowiec, J. (2018). Cariprazine—A novel antipsychotic drug and its place in the treatment of schizophrenia. Psychiatria Polska, 52(6), 971–981. https://doi.org/10.12740/PP/OnlineFirst/80710
Do, A., Keramatian, K., Schaffer, A., & Yatham, L. (2021). Cariprazine in the treatment of bipolar disorder: Within and beyond clinical trials. Frontiers in Psychiatry, 12, Article 769897. https://doi.org/10.3389/fpsyt.2021.769897
Vieta, E., McIntyre, R. S., Yu, J., Aronin, L. C., Kramer, K., & Nguyen, H. B. (2024). Full-spectrum efficacy of cariprazine across manic and depressive symptoms of bipolar I disorder in patients experiencing mood episodes: Post hoc analysis of pooled randomized controlled trial data. Journal of Affective Disorders, 366, 136–145. https://doi.org/10.1016/j.jad.2024.08.119
Lao, K. S., He, Y., Wong, I. C., Besag, F. M., & Chan, E. W. (2016). Tolerability and safety profile of cariprazine in treating psychotic disorders, bipolar disorder, and major depressive disorder: A systematic review with meta-analysis of randomized controlled trials. CNS Drugs, 30(11), 1043–1054. https://doi.org/10.1007/s40263-016-0382-z
Nasrallah, H. A., Earley, W., Cutler, A. J., Wang, Y., Lu, K., Laszlovszky, I., Németh, G., & Durgam, S. (2017). The safety and tolerability of cariprazine in long-term treatment of schizophrenia: A post hoc pooled analysis. BMC Psychiatry, 17, Article 305. https://doi.org/10.1186/s12888-017-1459-z
Cutler, A. J., Durgam, S., Wang, Y., Migliore, R., Lu, K., Laszlovszky, I., & Németh, G. (2018). Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: Results from a 1-year open-label study. CNS Spectrums, 23(1), 39–50. https://doi.org/10.1017/S1092852917000220
Barabássy, Á., Sebe, B., Acsai, K., Laszlovszky, I., Szatmári, B., Earley, W. R., & Németh, G. (2021). Safety and tolerability of cariprazine in patients with schizophrenia: A pooled analysis of eight phase II/III studies. Neuropsychiatric Disease and Treatment, 17, 957–970. https://doi.org/10.2147/NDT.S301225
Culpepper, L., Vieta, E., Kelly, D. L., Patel, M. D., Szatmari, B., Hankinson, A., & Earley, W. R. (2022). Minimal effects of cariprazine on prolactin levels in bipolar disorder and schizophrenia. Neuropsychiatric Disease and Treatment, 18, 995–1011. https://doi.org/10.2147/NDT.S348143
Kane, J. M., Zukin, S., Wang, Y., Lu, K., Ruth, A., Nagy, K., Laszlovszky, I., & Durgam, S. (2015). Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: Results from an international, phase III clinical trial. Journal of Clinical Psychopharmacology, 35(4), 367–373. https://doi.org/10.1097/JCP.0000000000000346
Earley, W., Durgam, S., Lu, K., Laszlovszky, I., Debelle, M., & Kane, J. M. (2017). Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: A pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. International Clinical Psychopharmacology, 32(6), 319–328. https://doi.org/10.1097/YIC.0000000000000187
Durgam, S., Starace, A., Li, D., Migliore, R., Ruth, A., Németh, G., & Laszlovszky, I. (2014). An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial. Schizophrenia Research, 152(2–3), 450–457. https://doi.org/10.1016/j.schres.2013.11.041
Durgam, S., Greenberg, W. M., Li, D., Lu, K., Laszlovszky, I., Németh, G., Migliore, R., & Volk, S. (2017). Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: Results from a 48-week, single-arm, open-label extension study. Psychopharmacology, 234(2), 199–209. https://doi.org/10.1007/s00213-016-4450-3
Durgam, S., Earley, W., Lipschitz, A., Guo, H., Laszlovszky, I., Németh, G., Vieta, E., Calabrese, J. R., & Yatham, L. N. (2016). An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. The American Journal of Psychiatry, 173(3), 271–281. https://doi.org/10.1176/appi.ajp.2015.15020164
Earley, W., Durgam, S., Lu, K., Laszlovszky, I., Debelle, M., Vieta, E., & Yatham, L. N. (2017). Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies. Journal of Affective Disorders, 215, 205–212. https://doi.org/10.1016/j.jad.2017.03.032
Earley, W., Burgess, M. V., Rekeda, L., Dickinson, R., Szatmári, B., Németh, G., McIntyre, R. S., Sachs, G. S., & Yatham, L. N. (2019). Cariprazine treatment of bipolar depression: A randomized double-blind placebo-controlled phase 3 study. The American Journal of Psychiatry, 176(6), 439–448. https://doi.org/10.1176/appi.ajp.2018.18070824
Earley, W. R., Burgess, M. V., Khan, B., Rekeda, L., Suppes, T., Tohen, M., & Calabrese, J. R. (2020). Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study. Bipolar Disorders, 22(4), 372–384. https://doi.org/10.1111/bdi.12852
Keramatian, K., Chithra, N. K., & Yatham, L. N. (2023). The CANMAT and ISBD guidelines for the treatment of bipolar disorder: Summary and a 2023 update of evidence. Focus, 21(4), 344–353. https://doi.org/10.1176/appi.focus.20230009
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. The Journal of Clinical Psychiatry, 65(2), 267–272. https://doi.org/10.4088/JCP.v65n0219
De Hert, M., Vancampfort, D., Correll, C. U., Mercken, V., Peuskens, J., Sweers, K., van Winkel, R., & Mitchell, A. J. (2011). Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: Systematic evaluation. The British Journal of Psychiatry, 199(2), 99–105. https://doi.org/10.1192/bjp.bp.110.084665
Mitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U., & De Hert, M. (2012). Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: Systematic review and meta-analysis of screening practices. Psychological Medicine, 42(1), 125–147. https://doi.org/10.1017/S003329171100105X
Mitchell, A. J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., & De Hert, M. (2013). Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders: A systematic review and meta-analysis. Schizophrenia Bulletin, 39(2), 306–318. https://doi.org/10.1093/schbul/sbr148
Vancampfort, D., Vansteelandt, K., Correll, C. U., Mitchell, A. J., De Herdt, A., Sienaert, P., Probst, M., & De Hert, M. (2013). Metabolic syndrome and metabolic abnormalities in bipolar disorder: A meta-analysis of prevalence rates and moderators. The American Journal of Psychiatry, 170(3), 265–274. https://doi.org/10.1176/appi.ajp.2012.12050620
Vancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., Rosenbaum, S., & Correll, C. U. (2015). Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder, and major depressive disorder: A systematic review and meta-analysis. World Psychiatry, 14(3), 339–347. https://doi.org/10.1002/wps.20252
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., Kane, J. M., Lieberman, J. A., Schooler, N. R., Covell, N., Stroup, T. S., Weissman, E. M., Wirshing, D. A., Hall, C. S., Pogach, L., Pi-Sunyer, X., Bigger, J. T., Jr., Friedman, A., Kleinberg, D., . . . Shon, S. (2004). Physical health monitoring of patients with schizophrenia. The American Journal of Psychiatry, 161(8), 1334–1349. https://doi.org/10.1176/appi.ajp.161.8.1334
Castle, D., & Li, A. (2023). Physical health monitoring for people with schizophrenia. Australian Prescriber, 46(4), 75–79. https://doi.org/10.18773/austprescr.2023.024
Owen, R. R., Drummond, K. L., Viverito, K. M., Marchant, K., Pope, S. K., Smith, J. L., Landes, R. D., Norman, S. R., Schoenbaum, M., & Kirchner, J. E. (2013). Monitoring and managing metabolic effects of antipsychotics: A cluster randomized trial of an intervention combining evidence-based quality improvement and external facilitation. Implementation Science, 8, Article 120. https://doi.org/10.1186/1748-5908-8-120
Mitchell, A. J., Vancampfort, D., De Herdt, A., Yu, W., & De Hert, M. (2013). Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first-episode, untreated, and treated patients. Schizophrenia Bulletin, 39(2), 295–305. https://doi.org/10.1093/schbul/sbs082
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Klaudia Magdalena Kotlarska, Wojciech Kotlarski, Tomasz Mainka, Emil Sergejuk
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
